S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
S&P 500   4,596.49 (+0.65%)
DOW   34,599.63 (+0.34%)
QQQ   393.43 (-0.10%)
AAPL   167.41 (+1.28%)
MSFT   334.33 (+1.13%)
FB   316.74 (-2.38%)
GOOGL   2,864.36 (+0.93%)
AMZN   3,479.79 (-0.78%)
TSLA   1,123.58 (-1.85%)
NVDA   321.39 (-1.64%)
BABA   124.46 (-2.41%)
NIO   39.20 (+0.18%)
CGC   10.23 (-4.48%)
AMD   151.44 (-4.38%)
GE   94.63 (-0.38%)
MU   86.63 (+3.13%)
T   22.39 (-1.93%)
F   19.84 (+3.39%)
DIS   144.21 (-0.48%)
PFE   55.12 (+2.59%)
ACB   6.15 (-4.21%)
AMC   30.58 (-9.90%)
BA   192.37 (-2.77%)
NASDAQ:PMD

Psychemedics Stock Forecast, Price & News

$7.84
-0.28 (-3.45%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
$7.84
$8.31
50-Day Range
$7.56
$8.79
52-Week Range
$4.13
$8.90
Volume
5,192 shs
Average Volume
26,777 shs
Market Capitalization
$43.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.75
30 days | 90 days | 365 days | Advanced Chart
Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.


Psychemedics logo

About Psychemedics

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Headlines

Contrasting Psychemedics (PMD) and Its Rivals
November 30, 2021 |  americanbankingnews.com
Financial Analysis: Psychemedics (PMD) versus Its Peers
November 28, 2021 |  americanbankingnews.com
Psychemedics (PMD) versus Its Rivals Critical Contrast
November 26, 2021 |  americanbankingnews.com
Contrasting Psychemedics (PMD) & Its Rivals
November 25, 2021 |  americanbankingnews.com
Psychemedics (PMD) vs. The Competition Critical Contrast
November 25, 2021 |  americanbankingnews.com
Financial Analysis: Psychemedics (PMD) and Its Rivals
November 23, 2021 |  americanbankingnews.com
Comparing Psychemedics (PMD) & Its Peers
November 23, 2021 |  americanbankingnews.com
Head to Head Contrast: Psychemedics (PMD) & Its Peers
November 21, 2021 |  americanbankingnews.com
Psychemedics Co. (NASDAQ:PMD) Short Interest Update
November 21, 2021 |  americanbankingnews.com
Financial Review: Psychemedics (PMD) and Its Rivals
November 19, 2021 |  americanbankingnews.com
Reviewing Psychemedics (PMD) & Its Rivals
November 17, 2021 |  americanbankingnews.com
Psychemedics (PMD) vs. Its Competitors Critical Comparison
November 16, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PMD
Employees
138
Year Founded
1985

Sales & Book Value

Annual Sales
$21.36 million
Book Value
$2.26 per share

Profitability

Net Income
$-3.86 million
Pretax Margin
-10.02%

Debt

Price-To-Earnings

Miscellaneous

Free Float
4,805,000
Market Cap
$43.45 million
Optionable
Not Optionable

Company Calendar

Last Earnings
4/23/2019
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/22/2022

Social Links


MarketRank

Overall MarketRank

1.32 out of 5 stars

Medical Sector

1146th out of 1,392 stocks

Medical Laboratories Industry

27th out of 30 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Psychemedics (NASDAQ:PMD) Frequently Asked Questions

How has Psychemedics' stock been impacted by Coronavirus?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PMD shares have increased by 12.8% and is now trading at $7.84.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Psychemedics?

Psychemedics saw a drop in short interest in November. As of November 15th, there was short interest totaling 18,700 shares, a drop of 30.5% from the October 31st total of 26,900 shares. Based on an average trading volume of 21,800 shares, the short-interest ratio is presently 0.9 days. Approximately 0.4% of the shares of the company are short sold.
View Psychemedics' Short Interest
.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for Psychemedics
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) posted its quarterly earnings data on Tuesday, April, 23rd. The company reported $0.11 EPS for the quarter. The company earned $9.82 million during the quarter. Psychemedics had a negative trailing twelve-month return on equity of 11.16% and a negative net margin of 6.42%.
View Psychemedics' earnings history
.

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:
  • Raymond C. Kubacki, Chairman, President & Chief Executive Officer
  • Charles M. Doucot, Executive Vice President
  • Sarah E. Ashby, Vice President & General Counsel
  • Andrew Limbek, Vice President & Controller
  • Michael I. Schaffer, Vice President-Laboratory Operations

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics CEO Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among Psychemedics' employees.

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

Who are Psychemedics' major shareholders?

Psychemedics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (6.74%), Crawford Investment Counsel Inc. (5.07%), Dimensional Fund Advisors LP (1.37%), Tieton Capital Management LLC (1.07%), Geode Capital Management LLC (0.62%) and Moors & Cabot Inc. (0.54%). Company insiders that own Psychemedics stock include Fred J Weinert, Michael I Schaffer and Raymond C Kubacki Jr.
View institutional ownership trends for Psychemedics
.

Which major investors are selling Psychemedics stock?

PMD stock was sold by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Dimensional Fund Advisors LP, Renaissance Technologies LLC, and Crawford Investment Counsel Inc..
View insider buying and selling activity for Psychemedics
or view top insider-selling stocks.

Which major investors are buying Psychemedics stock?

PMD stock was acquired by a variety of institutional investors in the last quarter, including Moors & Cabot Inc., HighMark Wealth Management LLC, and Geode Capital Management LLC. Company insiders that have bought Psychemedics stock in the last two years include Fred J Weinert, Michael I Schaffer, and Raymond C Kubacki Jr.
View insider buying and selling activity for Psychemedics
or or view top insider-buying stocks.

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $7.84.

How much money does Psychemedics make?

Psychemedics has a market capitalization of $43.45 million and generates $21.36 million in revenue each year. The company earns $-3.86 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does Psychemedics have?

Psychemedics employs 138 workers across the globe.

When was Psychemedics founded?

Psychemedics was founded in 1985.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

Where are Psychemedics' headquarters?

Psychemedics is headquartered at 289 GREAT ROAD Suite 200, ACTON MA, 01720.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at (978) 206-8220 or via fax at 978-264-9236.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.